Clinical Trials - May 14, 2015
Ebola Vaccine Regimen Tested
Preliminary results from a Phase 1 first-in-human study of the Ebola prime-boost vaccine regimen of Bavarian Nordic’s MVA-BN® Filo vaccine and the AdVac® vaccine from the Janssen Pharmaceutical Companies of Johnson & Johnson were presented by Janssen at a meeting of the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee. […]
Clinical Trials - December 8, 2014
Bavarian Nordic vs Ebola
Denmark’s Bavarian Nordic announced Dec. 4 that a first subject has been dosed with MVA-BN Filo in a Phase 1 safety and immunogenicity trial, evaluating a heterologous prime-boost regimen of Ebola candidate vaccines. The trial, sponsored by the University of Oxford, is assessing the monovalent cAd3-EBO Z vaccine co-developed by GSK and the U.S. National […]
